Finding the Way Forward: Can Gene and Cell Therapy Change the Paradigm?
Technology Spotlight – Gene and Cell Therapy
10:10 AM - 10:40 AM
Ekta Patel, PhD joined Mustang Bio in June 2018 as the Head of Pre-Clinical and Translational Sciences. Ekta brings scientific leadership and a successful track record of drug discovery and early development. An immunologist by training, Ekta is passionate about developing next generation cell and gene therapies to transform treatment paradigms. At Mustang, she is leading translational research to conduct efficacy and mechanism of action studies for cell and gene therapy programs in collaboration with City of Hope, Nationwide Children’s Hospital and Saint Jude’s Children’s Research Hospital.
Previously, Ekta was Head of Research at TCR2 Therapeutics in Cambridge, Massachusetts where she helped shape the development of TRuC platform (gene engineered T cells) from concept to clinic, by providing strategic, scientific and technical expertise. She has played a pivotal role in leading collaborations with Massachusetts General Hospital (MGH), University of Munich, University of Freiburg, Harvard University, for development and characterization of TRuC T cell therapy for hematological and solid tumors. Ekta started her drug discovery career at Sanofi-Genzyme and was responsible for advancing the company’s bispecific antibody program for the treatment of autoimmune diseases.
Ekta received her PhD from University of Florida where she studied the role of cytokines in T cell development. She continued her work on cytokines as a post-doctoral Fellow at Forsyth Institute-Harvard.